# Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression

> **NCT06975332** · NA · RECRUITING · sponsor: **Medical University of Warsaw** · enrollment: 35 (estimated)

## Conditions studied

- Glioblastoma
- High-Grade Gliomas
- Grade III Astrocytoma
- Grade III Glioma

## Interventions

- **RADIATION:** Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)

## Key facts

- **NCT ID:** NCT06975332
- **Lead sponsor:** Medical University of Warsaw
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-09
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975332, "Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06975332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*